ArticlePLoS neglected tropical diseases2018
Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 153 citations in OpenAlex.
- Cystic echinococcosis in Austria 2009-2024: national surveillance and two rare cases of musculoskeletal manifestations including clinical management strategies.BMC musculoskeletal disorders · 2026Article
- Detection of Echinococcus multilocularis in coyotes in Washington State, USA highlights need for increased wildlife surveillance.PLoS neglected tropical diseases · 2026Article
- Article
- The impact of radical hepatectomy on prognosis of patients with hepatic alveolar echinococcosis complicated with microvascular invasion.Scientific reports · 2025Article
- Characterization of Calcifying Nanoparticles Isolated and Cultured in the Outer Capsule Wall of Hepatic Hydatid Cyst and their Correlation with Autophagy.Acta parasitologica · 2025Article
- Antibacterial, antioxidant, and scolicidal activity investigation of biosynthesized ZnO NPs usingRSC advances · 2025Article
- Case Report: Primary splenic hydatid cyst.Frontiers in medicine · 2025Article
- Current status of drug therapy for alveolar echinococcosis.World journal of hepatology · 2024Review
- Article
- Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond.Parasitology · 2024Article
- In silico comparative analysis of cestode and human NPC1 provides insights for ezetimibe repurposing to visceral cestodiases treatment.Scientific reports · 2024Article
- Therapeutic Options in Hydatid Hepatic Cyst Surgery: A Retrospective Analysis of Three Surgical Approaches.Diagnostics (Basel, Switzerland) · 2024Article
- A Case Series and Literature Review of Alveolar Echinococcosis in Kashmir, India: An Emerging Endemic Zone forLife (Basel, Switzerland) · 2024Article
- Metabolic mechanism and pharmacological study of albendazole in secondary hepatic alveolar echinococcosis (HAE) model rats.Antimicrobial agents and chemotherapy · 2024Article
- Therapeutic effect of curcumin nanoemulsion on cystic echinococcosis in BALB/c mice: a computerized tomography (CT) scan and histopathologic study evaluation.BMC complementary medicine and therapies · 2024Article
- Article
- Laparoscopic Management of Multiple Liver, Omental, Mesenteric, Peritoneal, and Round Ligament Hydatid Cysts-A Rare Report of a Case and a Systematic Literature Review.Journal of personalized medicine · 2024Review
- Cystic Echinococcosis in the Early 2020s: A Review.Tropical medicine and infectious disease · 2024Review
- Evaluation of the Protoscolicidal Activity ofEvidence-based complementary and alternative medicine : eCAM · 2024Article
- ROS are required for the germinative cell proliferation and metacestode larval growth ofFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cystic and alveolar echinococcosis are helmintic zoonotic diseases caused by infections with the larval stages of the cestode parasites Echinococcus granulosus and E. multilocularis, respectively. Both diseases are progressive and chronic, and often fatal if left unattended for E. multilocularis. As a treatment approach, chemotherapy against these orphan and neglected diseases has been available for more than 40 years. However, drug options were limited to the benzimidazoles albendazole and mebendazole, the only chemical compounds currently licensed for treatment in humans. To compensate this therapeutic shortfall, new treatment alternatives are urgently needed, including the identification, development, and assessment of novel compound classes and drug targets. Here is presented a thorough overview of the range of compounds that have been tested against E. granulosus and E. multilocularis in recent years, including in vitro and in vivo data on their mode of action, dosage, administration regimen, therapeutic outcomes, and associated clinical symptoms. Drugs covered included albendazole, mebendazole, and other members of the benzimidazole family and their derivatives, including improved formulations and combined therapies with other biocidal agents. Chemically synthetized molecules previously known to be effective against other infectious and non-infectious conditions such as anti-virals, antibiotics, anti-parasites, anti-mycotics, and anti-neoplastics are addressed. In view of their increasing relevance, natural occurring compounds derived from plant and fungal extracts are also discussed. Special attention has been paid to the recent application of genomic science on drug discovery and clinical medicine, particularly through the identification of small inhibitor molecules tackling key metabolic enzymes or signalling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.